High rates of renal tubular damage in HBV monoinfected patients long-term treated with tenofovir: A cross-sectional, single center, real-life study in 414 patients

2017 ◽  
Vol 49 (1) ◽  
pp. e9
Author(s):  
G. Grossi ◽  
A. Loglio ◽  
F. Facchetti ◽  
E. Galmozzi ◽  
M. Colombo ◽  
...  
Keyword(s):  
Real Life ◽  
Tubular Damage ◽  
Single Center ◽  
Renal Tubular Damage ◽  
Cross Sectional ◽  
Life Study ◽  
Real Life Study ◽  
Renal Tubular

scholarly journals Mask side-effects in long-term CPAP-patients impact adherence and sleepiness: the InterfaceVent real-life study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Marie-Caroline Rotty ◽  
Carey M. Suehs ◽  
Jean-Pierre Mallet ◽  
Christian Martinez ◽  
Jean-Christian Borel ◽  
...  
Keyword(s):  
Side Effects ◽  
Demographic Data ◽  
Real Life ◽  
Cross Sectional Study ◽  
Apnea Hypopnea Index ◽  
Cross Sectional ◽  
Life Study ◽  
Patient Reported ◽  
Real Life Study

Abstract Background For some patients, Continuous Positive Airway Pressure (CPAP) remains an uncomfortable therapy despite the constant development of technological innovations. To date, no real life study has investigated the relationship between mask related side-effects (MRSEs) and CPAP-non-adherence (defined as < 4 h/day) or residual-excessive-sleepiness (RES, Epworth-Sleepiness-Scale (ESS) score ≥ 11) in the long-term. Methods The InterfaceVent-CPAP study is a prospective real-life cross-sectional study conducted in an apneic adult cohort undergoing at least 3 months of CPAP with unrestricted mask-access (34 different masks). MRSEs were evaluated using visual-analogue-scales, CPAP-data using CPAP-software, sleepiness using ESS. Results 1484 patients were included in the analysis (72.2% male, median age 67 years (IQ25–75: 60–74), initial Apnea–Hypopnea-Index (AHI) of 39 (31–56)/h, residual AHIflow was 1.9 (0.9–4) events/h), CPAP-treatment lasted 4.4 (2.0–9.7) years, CPAP-usage was 6.8 (5.5–7.8) h/day, the prevalence of CPAP-non-adherence was 8.6%, and the prevalence of RES was 16.17%. Leak-related side-effects were the most prevalent side-effects (patient-reported leaks concerned 75.4% of responders and had no correlation with CPAP-reported-leaks). Multivariable logistic regression analyses evaluating explanatory-variable (demographic data, device/mask data and MRSEs) effects on variables-of-interest (CPAP-non-adherence and RES), indicated for patient-MRSEs significant associations between: (i) CPAP-non-adherence and dry-mouth (p = 0.004); (ii) RES and patient-reported leaks (p = 0.007), noisy mask (p < 0.001), dry nose (p < 0.001) and harness pain (p = 0.043). Conclusion In long-term CPAP-treated patients, leak-related side-effects remain the most prevalent side-effects, but patient-reported leaks cannot be predicted by CPAP-reported-leaks. Patient-MRSEs can be independently associated with CPAP-non-adherence and RES, thus implying a complementary role for MRSE questionnaires alongside CPAP-device-reported-data for patient monitoring. Trial registration InterfaceVent is registered with ClinicalTrials.gov (NCT03013283).

Sa1825 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT

2020 ◽  
Vol 158 (6) ◽  
pp. S-441
Author(s):  
Daniela Pugliese ◽  
Giuseppe Privitera ◽  
Federica Crispino ◽  
Nicolò Mezzina ◽  
Lucienne Pellegrini ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Real Life ◽  
The Elderly ◽  
Life Study ◽  
Inflammatory Bowel ◽  
Real Life Study ◽  
Elderly Cohort

Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study

2021 ◽  
Vol 42 (3) ◽  
pp. 235-242 ◽  
Author(s):  
Andriana I. Papaioannou ◽  
Myrto Mplizou ◽  
Konstantinos Porpodis ◽  
Evangelia Fouka ◽  
Eleftherios Zervas ◽  
...  
Keyword(s):  
Lung Function ◽  
Adverse Events ◽  
Allergic Asthma ◽  
Asthma Control ◽  
Real Life ◽  
Efficacy And Safety ◽  
Life Study ◽  
Long Term Treatment ◽  
Real Life Study

Background: The efficacy and safety of omalizumab in patients with severe allergic asthma have been established in both randomized controlled trials and real-life studies. Objective: To evaluate the sustained effectiveness and safety of long-term treatment with omalizumab in a real-world setting. Methods: In this retrospective study, we included patients treated with omalizumab for at least 8 years in four asthma clinics in Greece. Pulmonary function, asthma control, oral corticosteroids (OCS) dose, and exacerbations were recorded before treatment, 6 months later, and annually thereafter. Adverse events were also recorded. Results: Forty-five patients (66.7% women), mean ± standard deviation (SD) age 55.3 ± 12.2 years, were included. The duration of treatment with omalizumab was 10.6 ± 1.2 years. The annual exacerbation rate decreased from 4.1 before omalizumab initiation to 1.1 after 1 year of treatment and remained low up to the 8th year of treatment (p < 0.001). From the 19 patients who were receiving OCS at baseline, 21.1% patients discontinued after 6 months, 47.4% were still on OCS after 4 years of therapy, and 31.6% were on OCS after 8 years. With regard to the OCS dose, 36.8% of the patients reduced the dose ≥ 50% after 6 months and 68.4% achieved 50% reduction after 2 years. The mean daily OCS dose before omalizumab initiation was 7.8 mg of prednisolone or the equivalent, reduced to 4.7 mg/day after 6 months, which reached 1.6 mg/day after 8 years (p < 0.001). Treatment with omalizumab resulted in significant improvements of asthma control and lung function. No severe adverse events were reported. Conclusion: In this real-life study, omalizumab resulted in significant and sustained improvements in asthma exacerbations, asthma control, and lung function, and had a steroid sparing effect and a good safety profile.

Sign in / Sign up

Export Citation Format

Share Document